Lenz Therapeutics announces FDA acceptance of NDA for LNZ100
LENZ Therapeutics (LENZ) announced that the U.S. Food and Drug Administration, FDA, has accepted the Company’s New Drug Application, NDA, for LNZ100 for the treatment of presbyopia, a condition ...
Monthly Prescribing Reference10h
Aceclidine-Based Eye Drop Under Review for Presbyopia
LNZ100 is a single-use, once-daily eye drop containing aceclidine, a small molecule acetylcholine receptor agonist that causes miosis.
Why LENZ Therapeutics Stock Hit A New 52-Week High Today
Lenz Therapeutics shares hit a new 52-week high during Monday's session. The company announced the FDA accepted its new drug ...
LENZ Therapeutics Shares Rise After FDA Accepts Application for Potential Eye Condition Treatment
LENZ Therapeutics said the submission for the treatment of presbyopia is supported by the positive data results from a Phase 3 study. Aceclidine is a new chemical entity in the U.S. and isn't approved ...